Maynard Um
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $35 at Leerink Partners
-
-
-
-
-
-
-
Intellia presents longer-term data for hereditary angioedema treatment
-
-
-
-
-
-
-
William Blair Upgrades Intellia Therapeutics (NTLA) to Outperform
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $7 at Baird
-
-
-
-
-
-
-
JPMorgan Downgrades Intellia Therapeutics (NTLA) to Underweight
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on Intellia Therapeutics (NTLA)
-
-
-
-
-
-
-
Intellia Therapeutics Stock Alert: Securities Investigation on Behalf of Intellia Investors - Contact Kehoe Law Firm, P.C. - NTLA
-
396,423 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

